Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

'Totality Of Data' Make A Case For Luspatercept In Beta-Thalassemia, MDS

03 Dec 2018

• By Mandy Jackson

3-D Rendering Red Blood Cells

Related Content

ASH Preview: Practice-Changing Darzalex And Imbruvica, Advances In Beta-Thalassemia And More

29 Nov 2018

Attention Turns To Celgene's Other Pipeline Prospects Following Second Positive Luspatercept Read-Out

10 Jul 2018

Celgene Notches A Needed Win As Acceleron-Partnered Luspatercept Succeeds In MDS

29 Jun 2018

Related Companies

Acceleron Pharma, Inc.

Bristol Myers Squibb Company

University of Milan

Incyte Corporation

Additional Topics

Clinical Trials Reimbursement Research & Development Blood & Coagulation Disorders BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.